Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MYND Life Sciences Inc C.MYND

Alternate Symbol(s):  MYNDF

MYND Life Sciences Inc. is a Canada-based life science based, neuro-pharmaceutical drug development company. The Company is working on advancing medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials, with an initial focus on major depressive disorder (MDD). Its lead development program, referred to as the human mycogene modulation program (HMM), is... see more

Recent & Breaking News (CSE:MYND)

MYND Life Sciences Announces New Testing Methodologies for Measuring Cellular Responses to Microdosing with Psilocybins

Newsfile June 1, 2022

MYND Life Sciences (CSE:MYND) announces $3.5M non-brokered private placement

John Ballem  April 22, 2022

MYND Life Sciences Announces $3.5 Million Share Offering

Newsfile April 21, 2022

MYND Life Sciences (CSE:MYND) executes MOU with Tidal Psychedelics

Brieanna McCutcheon  March 16, 2022

MYND Life Sciences Executes a Non-Binding MOU with Tidal Psychedelics

Newsfile March 16, 2022

MYND Life Sciences Inc. Announces the Recruitment of a Senior Operations and Research Manager

Newsfile March 9, 2022

MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial

PR Newswire February 8, 2022

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

PR Newswire January 12, 2022

MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other Dementias

PR Newswire December 17, 2021

MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

PR Newswire December 15, 2021

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

PR Newswire November 30, 2021

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

PR Newswire November 18, 2021

MYND Diagnostics Commences Clinical Research on Alzheimer's Disease

PR Newswire November 16, 2021

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist

PR Newswire November 9, 2021

MYND Life Sciences Announces Appointment of New Director

PR Newswire October 28, 2021

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other Dementias

PR Newswire October 27, 2021

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

PR Newswire October 18, 2021

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

PR Newswire October 13, 2021

MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13

PR Newswire October 11, 2021

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary - MYND Diagnostics Ltd.

PR Newswire October 7, 2021